Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders

Phytotherapy Research

Volumn 24, Issue 3, 2010, Pages 317-324

  Kulkarni, S K ^a   Dhir, Ashish ^b  

^a PANJAB UNIVERSITY   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Berberine; Monoamines; Neurological disorders; Safety

Indexed keywords

4 IODO N [2 [4 (METHOXYPHENYL)1PIPERAZINYL]ETHYL]N 2 PYRIDINYLPYRIDINYLBENZAMIDE; 7 NITROINDAZOLE; 8 HYDROXY 2 (DI N PROPYLAMINO)TERTRALINE; AMFEBUTAMONE; ANXIOLYTIC AGENT; BERBERINE; BUSPIRONE; DESIPRAMINE; DIAZEPAM; FLUOXETINE; IMIPRAMINE; MAPROTILINE; METHYLENE BLUE; MIANSERIN; MOCLOBEMIDE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PENTAZOCINE; PLACEBO; PROGESTERONE; RIMCAZOLE; RITANSERIN; TRANYLCYPROMINE; TRAZODONE; UNCLASSIFIED DRUG; VALPROIC ACID; VENLAFAXINE; YOHIMBINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; MANIA; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; REVIEW; SCHIZOPHRENIA;

ALZHEIMER DISEASE; ANIMALS; BERBERINE; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MOLECULAR STRUCTURE;

EID: 77349115762     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2968     Document Type: Review

References (58)

1. Anis KV, Kuttan G, Kuttan R. 1999. Role of berberine as an adjuvant response modifier during tumor therapy in mice. Pharmacy and Pharmacology Communications 5: 697-700.
2. Asai M, Iwata N, Yoshikawa A, Aizaki Y, Ishiura S, Saido TC, Maruyama K. 2007. Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. Biochem Biophys Res Commun 352: 498-502.
3. Birdsall TC, Kelly GS. 1997. Berberine: Therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev 2: 94-103.
4. Chan E. 1993. Displacement of bilirubin from albumin by berberine. Biol Neonate 63: 201-208.
5. Chen CM, Chang HC. 1995. Determination of berberine in plasma, urine and bile by high-performance liquid chromatography. J Chromatogr B 665: 117-122.
6. Chopra RN. 1958. Indigenous Drugs. U. N. Dhur and Sons, Limited, Calcutta.
7. Chu H, Jin G, Friedman E, Zhen X. 2008. Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction. Cell Mol Neurobiol 28: 491-499.
8. Dastur JF. 1962. Useful plants of India and Pakistan, 5th ed. D.B. Taraporevala Sons, Bombay; 37-38.
9. Dhir A, Kulkarni SK. 2007. Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology 80: 239-243.
10. Dhir A, Naidu PS, Kulkarni SK. 2007. Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. Seizure 16: 691-697.
11. Doggrell SA. 2005. Berberine-a novel approach to cholesterol lowering. Expert Opin Investig Drugs 14: 683-685.
12. Eom KS, Hong JM, Youn MJ, So HS, Park R, Kim JM, Kim TY. 2008. Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol Pharm Bull 31: 558-562.
13. Gudima SO, Memelova LV, Borodulin VB, Pokholok DK, Mednikov BM, Tolkachev ON, Kochetkov SN. 1994. Kinetic analysis of interaction of human immunodeficiency virus reverse transcriptase with alkaloids. Mol Biol (Mosk) 28: 1308-1314.
14. Gulfraz M, Mehmood S, Ahmad A, Fatima N, Praveen Z, Williamson EM. 2008. Comparison of the antidiabetic activity of Berberis lyceum root extract and berberine in alloxan-induced diabetic rats. Phytother Res 22: 1208-1212.
15. Heiberg IL, Wegener G, Rosenberg R. 2002. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134: 479-484.
16. Huang W. 1990. Ventricular tachyarrhythmias treated with berberine. Zhonghua Xin Xue Guan Bing Za Zhi 18: 155-156.
17. Imanshahidi M, Hosseinzadeh H. 2008. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 22: 999-1012.
18. Ingkanian K, Phengpa P, Yuenyongsawad S, Khorana N. 2006. Acetylcholinesterase inhibitors from Stephania venosa tuber. J Pharm Pharmacol 58: 695-700.
19. Jahnke GD, Price CJ, Marr MC, Myers CB, George JD. 2006. Developmental toxicity evaluation of berberine in rats and mice. Birth Defects Res B Dev Reprod Toxicol 77: 195-206.
20. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19.
21. + T cells from a Th2 to a Th1 response. Immunology 109: 407-414.
22. Kong LD, Cheng CH, Tan RX. 2001. Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med 67: 74-76.
23. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351.
24. Kong WJ, Wei J, Zuo ZY, Wang YM, Song DQ, You XF, Zhao LX, Pan HN, Jiang JD. 2008. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism 57: 1029-37.
25. Kulkarni SK, Dhir A. 2007. Possible involvement of L-argininenitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur J Pharmacol 569: 77-83.
26. Kulkarni SK, Dhir A. 2008. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 589: 163-172.
27. Kuznetsova LP, Sochilina EE, Faddeeva MD, Iagodina OV. 2005. Effect of some isoquinoline alkaloids on enzymatic activity of acetylcholinesterase and monoamine oxidase. Ukr Biokhim Zh 77: 147-153
28. Lee B, Yang CH, Hahm DH, Lee HJ, Choe ES, Pyun KH, Shim I. 2007. Coptidis Rhizoma attenuates repeated nicotine-induced behavioural sensitization in the rat. J Pharm Pharmacol 59: 1663-1669.
29. Liu WH, Hei ZQ, Nie H, Tang FT, Huang HQ, Li XJ, Deng YH, Chen SR, Guo FF, Huang WG, Chen FY, Liu PQ. 2008. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J (Engl) 121: 706-712.
30. Ma L, Xiao P, Guo B, Wu J, Liang F, Dong S. 1999. Cerebral protective effects of some compounds isolated from traditional Chinese herbs. Zhongguo Zhong Yao Za Zhi 24: 238-239.
31. Maes M. Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. 1995. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Research 58: 217-225.
32. Marin-Neto JA, Maciel BC, Secches AL, Gallo Junior L. 1988. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol 11: 253-260.
33. Millan MJ. 2004. The role of monoamines in the actions of established and 'novel' antidepressant agents: a critical review. Eur J Pharmacol 500: 371-384.
34. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. 2002. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 91: 193-197.
35. Papassotiropoulos A, Streffer JR, Hock C, Nitsch RM. 2001. Genetics of Alzheimer's diseases. Schweizer Archiv für Neurologie und Psychiatrie 152: 278-287
36. Peng WH, Lo KL, Lee YH, Hung TH, Lin YC. 2007. Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice. Life Sci 81: 933-938.
37. Peng WH, Wu CR, Chen CS, Chen CF, Leu ZC, Hsieh MT. 2004. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. Life Sci 2004 75: 2451-2462.
38. Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao X. 2008. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 36: 2159-2165.
39. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. 1987. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis 155: 979-984.
40. Rea D, Fülöp V. 2006. Structure-function properties of prolyl oligopeptidase family enzymes. Cell Biochem Biophys 44: 349-365.
41. Sabir M, Bhide NK. 1971. Study of some pharmacological actions of berberine. Indian J Physiol Pharmacol 15: 111-132.
42. Tarrago T, Kichik N, Seguí J, Giralt E. 2007. The Natural Product Berberine is a Human Prolyl Oligopeptidase Inhibitor. ChemMedChem 2: 354-359.
43. Wang F, Zhao G, Cheng L, Zhou HY, Fu LY, Yao WX. 2004. Effects of berberine on potassium currents in acutely isolated CA1 pyramidal neurons of rat hippocampus. Brain Res 999: 91-97.
44. Wang X, Wang R, Xing D, Su H, Ma C, Ding Y, Du L. 2005a. Kinetic difference of berberine between hippocampus and plasma in rat after intravenous administration of Coptidis rhizoma extract. Life Sci 77: 3058-3067.
45. Wang X, Xing D, Wang W, Su H, Tao J, Du L. 2005b. Pharmacokinetics of berberine in rat thalamus after intravenous administration of Coptidis rhizoma extract. Am J Chin Med 33: 935-943.
46. Wu JF, Liu TP, Wang JX, Yang SJ. 1997. Effect of berberine on intracellular free CA2+ concentration in cultured brain cells. Yao Xue Xue Bao 32: 15-18.
47. Wu JF, Liu TP. 1995. Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion. Yao Xue Xue Bao. 30: 98-102.
48. Xu MG, Wang JM, Chen L, Wang Y, Yang Z, Tao J. 2008. Berberine-induced mobilization of circulating endothelial progenitor cells improves human small artery elasticity. J Hum Hypertens 22: 389-393.
49. Yao WX, Fang DC, Cheng B, Jiang MX. 1987. Blocking action of berberine on alpha 2- and alpha 1-adrenoceptors in rat vas deferens and anococcygeus muscle. J Tongji Med Univ 7: 233-238.
50. Yao WX, Ling BD, Chen B, Han H, Fang DC, Jiang MX. 1986. Blocking action of berberine on alpha 2 and alpha 1 adrenoceptors in the rat vas deferens and anococcygeus muscle. Zhongguo Yao Li Xue Bao 7: 511-515.
51. Yin J, Xing H, Ye J. 2008. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 57: 712-717.
52. Yoo KY, Hwang IK, Kim JD, Kang IJ, Park J, Yi JS, Kim JK, Bae YS, Won MH. 2008. Antiinflammatory effect of the ethanol extract of Berberis koreana in a gerbil model of cerebral ischemia/reperfusion. Phytother Res 22: 1527-1532.
53. Yoo KY, Hwang IK, Lim BO, Kang TC, Kim DW, Kim SM, Lee HY, Kim JD, Won MH. 2006. Berberry extract reduces neuronal damage and N-Methyl-D-aspartate receptor 1 immunoreactivity in the gerbil hippocampus after transient forebrain ischemia. Biol Pharm Bull 29: 623-628.
54. Yuan ZZ, Zhu LQ, Pang H, Shan ZS, Wang SR, Gao YH, Niu FL. 2007. Protective action of effective components of Huanglian Jiedu decoction on hypoxia and reoxygenation injury in cultured rat cerebral microvascular endothelial cells. Zhongguo Zhong Yao Za Zhi 32: 249-252.
55. Zeng XH, Zeng XJ, Li YY. 2003. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. The American Journal of Cardiology 92: 173-176.
56. Zhang RX, Dougherty DV, Rosenblum ML 1990. Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1- nitrosourea to treat malignant brain tumors. Chin Med J (Engl) 103: 658-665.
57. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G. 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 93: 2559-2565.
58. Zhu F, Qian C. 2006. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci 7: 78.